Asia-Pacific Region (APAC).

Unlock Asia-Pacific Scale & Speed

Spanning 4.3 billion people—about 60 % of the world’s population—the Asia-Pacific (APAC) region is now the fastest-growing pharmaceutical arena, forecast to expand at ≈ 7 % CAGR through 2030 on sales already topping US $333 billion

Flexible Partnership Models

Select the structure that aligns with your capital plan:

  • Leasing – operating leases to suit your needs.

  • Project Finance – milestone-based funding that scales with your pipeline.

  • Rent-to-Own – build equity in critical facilities while you innovate.

Who We Serve

  • Global and domestic pharmaceutical companies scaling clinical or commercial production.

  • Public and private research institutes driving next-generation biologics.

  • Leading universities advancing translational science and talent development.

Why APAC?

  • Dense, integrated bio-clusters—from Singapore and Korea to India, Japan, Australia, and emerging hubs in Taiwan and New Zealand—deliver end-to-end supply-chain efficiency.

  • Rapid market expansion fuels demand for contract services, with APAC CDMO revenues projected to surge from ≈ US $60 billion in 2025 to US $91 billion by 2030.

  • Regional trade pacts (RCEP, CPTPP) reduce tariffs, harmonise standards, and smooth cross-border movement of talent, materials, and IP

  • Robust incentives—generous R&D tax credits, fast-track regulatory pathways, and production-linked grants—lower cost-of-capital and accelerate ROI.

  • Unmatched talent pool blending precision engineering in Japan and Korea, digital-biotech expertise in Australia and Singapore, and large-scale workforce depth in India and China.

Let’s Propel Discovery—Together

From green-field builds to capacity expansions to R&D, our team stands ready to make your APAC strategy seamless. Connect with us today to see how we can power your next breakthrough.